Vol.

No.

December 16, 2022Dec 16, 2022

DOWNLOAD THE PDF

NCI Director Monica Bertagnolli has breast cancer “I have more motivation to get up every morning to keep doing what I do”

Cover Story

Conversation with The Cancer Letter Free

NCI Director Monica Bertagnolli has breast cancer

“I have more motivation to get up every morning to keep doing what I do”

By Paul Goldberg and Matthew Bin Han Ong

Monica Bertagnolli, the 16th director of the National Cancer Institute, announced that she will be undergoing treatment for early-stage breast cancer.

Clinical

Moderna’s mRNA cancer vaccine improves survival in phase IIb melanoma study—first observation of efficacy in an RCT

By Matthew Bin Han Ong

NCI BSA approves eight new, reissue concepts at BSA/NCAB joint meeting

By Jacquelyn Cobb

In the Archives

The National Cancer Act 20 years later: impact as seen by its architects in 1991

In Brief

Ruben Mesa to lead Atrium Health’s cancer program at Wake Forest and Levine

Yolanda Sanchez named director and CEO at UNM Comprehensive Cancer Center

Congressional bill focuses on cancer survivorship

The Max Foundation to make Novartis’s Scemblix available in low- & middle-income countries

Funding Opportunities

FDA issues RFAs to study novel approaches to support therapeutic development in ultra-rare cancers

Fight Colorectal Cancer funds Tempus research fellowship to identify gaps in colorectal cancer research

Clinical Roundup

Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL

Phase III study shows long-term results of Darzalex-based regimen in newly diagnosed, transplant-ineligible MM

Phase II data on Regeneron’s linvoseltamab show clinically meaningful responses in heavily pre-treated MM

Positive phase II data reported on Regeneron’s odronextamab in R/R DLBCL

Drugs & Targets

FDA approves updated drug labeling for Xeloda tablets under Project Renewal

Tecentriq receives FDA approval for alveolar soft part sarcoma

Krazati receives FDA accelerated approval for KRAS G12C-mutated NSCLC

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues